Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dipyrone + chlorpheniramine + caffeine
- Development stage
- Unknown
- Lead developer
- Brainfarma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dipyrone monohydrate + chlorpheniramine maleate + caffeine is a fixed-dose combination (FDC) small molecule drug developed by Brainfarma Indústria Química e Farmacêutica S/A for the symptomatic treatment of the common cold and influenza. The combination consists of dipyrone (metamizole), a non-opioid analgesic and antipyretic that inhibits prostaglandin synthesis through the cyclooxygenase (COX) pathway; chlorpheniramine maleate, a first-generation H1 histamine receptor antagonist that relieves symptoms such as rhinorrhea and sneezing; and caffeine, a central nervous system stimulant and adenosine receptor antagonist that potentiates the analgesic effects of dipyrone. This FDC is currently being evaluated in the Phase III PANAMA clinical trial in Brazil, comparing its efficacy and safety to the reference product Benegrip and placebo.
- Other names
- dipyrone monohydrate + chlorpheniramine maleate + caffeinemetamizole + chlorpheniramine + caffeine
02
Targets
ADORA2A (Adenosine A₂A Receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HRH1 (Histamine H1 Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)ADORA1 (Adenosine receptor A1 subtype)
Beyond the preview
Go deeper on dipyrone + chlorpheniramine + caffeine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dipyrone + chlorpheniramine + caffeine.